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Targeting cholesterol at different levels in the 
mevalonate pathway protects fatty liver against 
ischemia-reperfusion injury. 
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ABSTRACT 
Background&Aims: Liver steatosis enhances ischemia/reperfusion (I/R) injury and is 
considered a primary factor in graft failure after liver transplantation. Although previous 
reports have shown a role for qualitative steatosis (macrovesicular vs. microvesicular) in 
hepatic I/R injury, no studies have compared side by side the specific contribution of 
individual lipids accumulating in fatty liver to I/R damage. Methods: We used 
nutritional and genetic models of micro and macrovesicular fatty livers exhibiting 
specific lipid profiles to assess their susceptibility to normothermic I/R injury. Results: 
Unlike choline-deficient  (CD) diet-fed mice, characterized by predominant liver 
triglycerides/free fatty acids (TG/FFA) accumulation, mice fed a cholesterol-enriched 
(HC) diet, which exhibited enhanced hepatic cholesterol loading in mitochondria, were 
highly sensitive to I/R-induced liver injury. In vivo two-photon confocal imaging 
revealed enhanced mitochondrial depolarization and generation of reactive oxygen 
species following hepatic I/R in HC-fed but not in CD-fed mice, consistent with 
decreased mitochondrial GSH (mGSH) observed in HC-fed mice. Moreover, ob/ob 
mice, characterized by increased hepatic TG, FFA and cholesterol levels, were as 
sensitive to I/R-mediated liver injury as mice fed the HC diet. Livers from ob/ob mice 
displayed increased StAR expression and mitochondrial cholesterol accumulation, 
resulting in mGSH depletion. Interestingly, atorvastatin therapy or squalene synthase 
inhibition in vivo attenuated StAR overexpression, mitochondrial cholesterol loading 
and mGSH depletion, protecting ob/ob mice from I/R-mediated liver injury. 
Conclusion: cholesterol accumulation, particularly in mitochondria, sensitizes to 
hepatic I/R injury, emerging as a novel target to prevent the enhanced damage of 
steatotic livers to I/R-mediated damage.  
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INTRODUCTION 
Liver transplantation is an effective treatment for chronic end-stage liver disease and 
acute liver failure. The decreasing number or quality of organs available for 
transplantation represents a serious hurdle for this therapy, leading to the use of 
suboptimal-quality grafts, such as steatotic livers, which may compromise the overall 
success of liver transplantation [1]. Due to the rising prevalence of obesity and type II 
diabetes among the general population, fatty livers constitute an expanding pool of 
marginal grafts available for transplantation. Hepatic steatosis is known to impose an 
additional risk of primary graft dysfunction [1]. Fat accumulation within hepatocytes 
increases cell volume resulting in a decreased sinusoidal space and impaired 
microcirculatory blood flow [2]. Nevertheless, the molecular underlying mechanisms 
the susceptibility of fatty livers to ischemia/reperfusion (I/R) injury remain 
incompletely understood.  
Based on the morphology, size and percentage of hepatocytes exhibiting cytoplasmic fat 
deposits, it has been previously reported that fatty livers with macrovesicular steatosis 
are more susceptible to I/R injury than those with microsteatosis, correlating with 
impaired hepatic perfusion and portal vein flow [3, 4]. However, the contribution of 
microvesicular steatosis to graft dysfunction after transplantation remains unclear. For 
instance, while some studies showed that livers with moderate microsteatosis are non-
functional after transplantation [5], other reports discarded a role for microvesicular 
steatosis on graft or patient survival [6, 7]. Hence, a better understanding of the 
mechanisms involved in the susceptibility of fatty livers to I/R injury may increase the 
availability of donor organs, providing a better chance for liver transplantation. 
Hepatic steatosis is characterized by the accumulation of a heterogeneous population of 
lipids, predominantly triglycerides (TG), free fatty acids (FFA) and cholesterol 
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(esterified and unsterified) [8]. While hepatic FFA and cholesterol can derive from 
adipose tissue or LDL uptake from the circulation, they can be synthesized de novo in 
the endoplasmic reticulum by pathways controlled at the transcriptional level by 
transcription factors SREBP-1c and SREBP-2, respectively [8, 9]. Triglycerides are 
synthesized from FFA and can be stored in lipid droplets or packed as VLDL particles 
for export to extrahepatic organs. Although previous studies have addressed the impact 
of qualitative steatosis (macrovesicular vs. microvesicular) to hepatic I/R injury [3-7], 
no studies have compared side-by-side the specific contribution of the individual lipids 
accumulating in fatty liver to I/R injury. In order to discern whether the type rather than 
the amount of fat contributes to the susceptibility of fatty livers to I/R injury, we used 
nutritional models of hepatic steatosis characterized by predominant TG/FFA or 
cholesterol accumulation by feeding a diet deficient in choline or enriched in 
cholesterol, respectively [10]. In addition, we used ob/ob mice, a genetic model of 
hepatic macrovesicular steatosis and cholesterol accumulation, to analyze the influence 
of cholesterol modulation by blocking hydroxymethylglutaryl CoA reductase 
(HMGCoAR), the regulatory enzyme in the mevalonate pathway which is 
transcriptionally controlled by SREBP-2, or by inhibition of squalene synthase, which 
catalyzes the first committed step towards cholesterol synthesis [11]. Our data indicate 
that cholesterol and its trafficking to mitochondria critically contributes to the 
susceptibility of fatty liver to I/R injury and that its targeting may represent a previously 
unrecognized opportunity for a better option in liver transplantation. 
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MATERIALS AND METHODS 
Animals, diets  and treatments.  
Male C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, 
MA). Ob/Ob mice (in the C57BL/6 background) were obtained from The Jackson 
Laboratories (Bar Harbor, Maine). 8-10 weeks old mice (the number of mice per group 
is detailed in the corresponding figure legend) were housed under specific pathogen-free 
conditions with controlled temperature and humidity on a 12 hr light-dark cycle. Mice 
were fed either a choline-deficient (CD) methionine sufficient diet or a sodium cholate-
supplemented hypercholesterolemic (2%, HC) diet for 2 days (Dyets Inc, Bethlehem, 
PA) as described previously [10]. Control mice received the standard chow pellets. 
Ob/ob mice were dosed daily by oral gavage with atorvastatin (Pfizer) (10mg/kg), the 
squalene synthase inhibitor YM-53601 (Sigma) (15mg/kg) or vehicle 7 days before 
being subjected to partial normothermic I/R. The experimental animal protocol was 
approved by the Institut d’Investigacions Biomèdiques Agustí Pi I Sunyer (IDIBAPS) 
Animal Care and Use Committee. 
Partial hepatic ischemia. 
Male wild-type mice were anesthesized using a vaporizer system to deliver 
isoflurane/O2 inhalation. After a midline laparotomy, hepatic inflow to the median and 
left lobes was occluded by application of a micro-vascular clamp (Biemer clip, 0.29-
0.39 N) for 60-90 min as described previously [12, 13] to prevent hepatic blood flow for 
90 minutes. Mesenteric venous congestion was prevented by portal decompression 
through the right and caudate lobes. Blood samples and liver biopsies were taken at 
different periods after reperfusion for further evaluation, typically 4-6 hours post-
reperfusion when massive liver injur is observed [12, 13]. Control animals were sham 
operated.  
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Mitochondria isolation.  
In some cases, livers after reperfusion were collected and processed for mitochondrial 
isolation by Percoll density gradient centrifugation, checking for mitochondrial purity 
and cross contamination with extramitochondrial compartments, as described previously 
[10, 14]. 
In vivo two-photon confocal imaging.  
Hepatic partial warm ischemia was performed for 60 minutes in mice fed the CD or HC 
diets. After reperfusion, the left lobe of the liver was taken out via an abdominal 
incision, gently pressuring the abdomen to allow the edge of the lobe to emerge as 
described before [15]. 2´-7´-dichlorofluorescein (DCF, 200mM, incubated for 45 min) 
and tetramethylrhodamine ethyl ester (TMRE, 5mM incubated for 30 min) to monitor 
reactive oxygen species generation and mitochondrial membrane potential, respectively, 
were added on the lobe for 30-45 minutes and imaged using one photon excitation at 
485nm and emission at 380- 520nm for the DCF and excitation at 516nm and emission 
at 582-677nm for the TMRE. Both emissions were acquired with internal spectral 
detector (PMT) at high speed (31 frames, line average 4) in order to avoid movement 
from animal breathing and heart beating during acquisition. Images were collected in a 
512 x 512 format, zoom 1.7 and pinhole completely open. Imaging of the liver of living 
mice was performed using spectral confocal inverted microscope Leica TCS SP5, 
equipped with 63x glycerol immersion (NA1.4) objective and near infrared laser 1.2 ps 
(titanium-saphire IR MaiTai Broad laser, 710-990nm, Broad Band, Spectra Physics), 
resonant scan (video rate speed) and incubation heating system. 
Biochemical determinations. 
 JHEPAT-D-10-00907-R Llacuna et al., 
  8 
TG, FFA and cholesterol in plasma or tissue were measured by the Centro de 
Diagnóstico Medico (Hospital Clinic, Barcelona, Spain). In brief,…. 
Total and unsterified cholesterol analysis. 
Total cholesterol determination in hepatic or mitochondrial extracts (5 mg) was 
performed upon saponification (alcoholic KOH at 60ºC for 30 minutes) followed by 
addition of 10 ml of hexane and 3 ml of distilled water. Hexane layer aliquots were 
evaporated under nitrogen and used for cholesterol measurement. Free cholesterol was 
determined from unsaponified samples and analyzed by HPLC using Bondapak C18 10-
lm reversed-phase column (30 cm, 4 mm inner diameter; Waters, Barcelona, Spain), and 
2-propanol:acetonitrile:water (60:30:10) as the mobile phase at a flow rate of 1 ml/min 
as described [10]. 
Total and mitochondrial GSH determination. 
GSH and GSSG in hepatic homogenates or mitochondrial fraction were measured after 
10% trichloroacetic acid precipitation by HPLC as described [16, 17]. In some cases, 
total GSH levels in either cytosol or mitochondria were determined by the recycling 
assay as reported previously [18, 19]. 
Liver damage and lipid peroxidation. 
After reperfusion, livers were fixed with…. and sections (5 μm) stained with 
hematoxylin and eosin (H&E) using standard methods and slides were examined with a 
Zeiss Axioplan microscope (Göttingen, Germany) equipped with a Nikon DXM1200F 
digital camera (Tokyo, Japan). Serum ALT levels were measured by the Centro de 
Diagnóstico Medico (Hospital Clinic, Barcelona, Spain). Lipid peroxidation in liver 
samples was determined after the production of malondialdehyde (MDA) using the 
thiobarbituric acid (TBA) method as described previously [13]. 
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StAR expression 
Hepatic StAR mRNA levels from ob/ob mice were determined by quantitative real-time 
RT-PCR analyses (primer sense, CCACCCCTAGCACGTGGA; primer antisense, 
TCCTGGTCACTGTAGAGAGTCTCTTC) using the…..(equipment description). RNA 
was extracted by TRIzol (Invitrogen) method following the manufacturer’s instructions 
under sterile conditions. RNA integrity and concentration were analysed by NanoDrop 
Spectrophotometer. Real-time PCR was performed with the iScript One-Step RT-PCR 
kit SYBR Green (Bio-Rad) with the following profile: 50 ng of total RNA, 600 nM of 
primers and 12.5 l of 2X Reaction Mix in a total volume of 25 l were incubated 10 
min at 50ºC, 5 min at 95ºC, followed for 45 cycles at 95ºC for 10s, 59ºC for 30s and 
72ºC for 30s. Each reaction was done in triplicate and the threshold values (C) for each 
mRNA were substracted from that of HRP mRNA, as a housekeeping gene, averaged 
and converted from log-linear to linear term. 
Statistical Analyses 
Results are expressed as mean SD. Experiments were performed routinely with at least 
4 to 6 animals per group. Statistical comparison of the mean values was performed 
using the Student’s t-test for unpaired data. MORE DESCRIPTION 
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RESULTS 
Nutritional and genetic models of hepatic steatosis with distinct lipid profile. 
Since our aim was to address the specific role of individual lipids accumulating in 
hepatic steatosis to I/R injury, we used nutritional models of fatty livers exhibiting a 
different lipid profile. Choline is an essential nutrient required for efficient 
phosphatidylcholine synthesis necessary for the packaging and export of VLDL 
particles to extrahepatic organs. Feeding mice a CD diet results in hepatic steatosis with 
predominant TG content and unchanged cholesterol levels compared to chow-fed mice 
(Fig 1A), consistent with previous reports [10, 20, 21]. In contrast, increased hepatic 
cholesterol levels but unchanged TG  content are observed in mice fed the HC diet (Fig 
1B). Filipin staining and HPLC analyses indicated that most of the total cholesterol 
levels are unsterified (Fig. 1B, D). In line with our prior observations, the content of 
FFA increased with respect to chow fed mice to a similar level in both CD or HC fed 
mice (Fig 1C). Oil red staining indicated the appearance of microvesicular steatosis 
with a strong filipin staining in HC-fed mice, while the steatosis of CD-fed mice was 
macrovesicular compared to HC-fed mice with little filipin staining (Fig 1D, E). Unlike 
CD or HC-fed mice, the liver of ob/ob mice is characterized by the presence of TG, 
FFA and cholesterol as revealed by biochemical determinations (Supplemental Fig 1), 
while oil-red and filipin staining indicated the appearance of large lipid droplets 
indicative of macrovesicular steatosis and free cholesterol accumulation (Fig. 1D, E). 
Thus, these nutritional and genetic models induce fatty liver with different lipid 
composition mainly enriched in TG or cholesterol and similar FFA content. 
HC-fed mice and ob/ob mice are more sensitive to hepatic I/R injury than CD-fed 
mice. 
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We next examined the susceptibility of CD or HC fed mice to partial hepatic I/R injury. 
Compared to sham controls, normothermic ischemia (90 minutes) followed by 6 hours 
after reperfusion resulted in significant release of serum ALT in control chow-fed mice 
and CD-fed mice  (Fig. 2A). However, the magnitude of ALT release in HC fed mice 
was significantly greater compared to control or CD-fed mice (Fig. 2A). In line with 
this outcome, histology analyses indicated that the liver damage in HC fed mice was 
more severe compared to mice fed the CD diet (Fig 2B). In addition, ob/ob mice, which 
exhibit genetic macrovesicular steatosis, were markedly sensitive to hepatic I/R injury 
compared to CD-fed mice, determined by transaminase release (Fig 2C) or histology 
analyses (Fig 2D), similar to the damage seen in mice fed the HC diet. Consistent with 
previous findings, the susceptibility of ob/ob mice to hepatic I/R was greater than that of 
CD-fed mice [3]. Thus, although the morphological and qualitative appearance of 
hepatic steatosis of HC-fed and ob/ob mice is strikingly different, displaying a 
microvesicular and macrovesicular pattern, respectively, both exhibit a high sensitivity 
towards hepatic I/R injury. Despite that TG are a predominant determinant of hepatic 
steatosis and a major component of lipid droplets [22], these data suggest that the 
presence of cholesterol rather than TG plays a significant role in the susceptibility to 
hepatic I/R injury. 
Mitochondrial cholesterol potentiates mitochondrial GSH depletion following I/R. 
Cholesterol is a critical bilayer component that distributes heterogenously among cell 
membranes. Although mitochondria are cholesterol-poor organelles, mitochondrial 
cholesterol has emerged as an important player in pathophysiology, including liver 
diseases such as steatohepatitis [11]. Therefore, we next evaluated the status of 
mitochondrial cholesterol in mice fed HC or CD diets. As seen, HC-fed mice but not 
CD-fed mice exhibited increased mitochondrial cholesterol content, and this particular 
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cholesterol pool was insensitive to I/R (Fig 3A), paralleling the increase seen in hepatic 
extracts (Fig. 1B). Moreover, since GSH homeostasis plays a critical role in hepatic I/R 
injury, we examined the status of total GSH vs that of the specific pool of GSH in 
mitochondria during I/R. The level of GSH in hepatic extracts decreased following I/R 
regardless of the nutritional regimen and independent of the hepatic lipid profile (Fig. 
3B). In contrast, the hepatic mitochondrial GSH content decreased significantly in sham 
HC-fed mice (Fig 3C), consistent with the negative impact of mitochondrial cholesterol 
in mitochondrial GSH transport [18, 23]. I/R depleted mitochondrial GSH in control 
and CD-fed mice, likely reflecting the decrease of cytosolic GSH (Fig. 3B). However, 
this effect of I/R on mitochondrial GSH depletion was further potentiated in HC-fed 
mice (Fig. 3C) because of the additional contribution of mitochondrial cholesterol 
loading. Thus, these findings correlate the susceptibility of HC-fed mice with increased 
mitochondrial cholesterol trafficking and subsequent mitochondrial GSH depletion.  
In vivo confocal imaging of fatty livers from mice fed CD or HC diets following 
I/R. 
The mechanisms underlying hepatic I/R injury are multifactorial, with the 
overgeneration of reactive oxygen species (ROS) playing a critical role. Moreover, 
mitochondria not only are a major source of ROS but they are instrumental in the 
predominant necrotic cell death during I/R injury via mitochondrial permeability 
transition (MPT) [24, 25]. Having observed the depletion of mitochondrial GSH in fatty 
livers of HC-fed mice, which are particularly susceptible to I/R damage, we next 
analyzed the burst of ROS and mitochondrial membrane potential in vivo by two-
photon confocal imaging of livers during I/R. ROS stimulation and mitochondrial 
membrane potential were recorded by DCF and TMRM labeling and imaged with an 
internal spectral detector at high speed to avoid the movement from animal breathing 
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and heart beating during acquisition. As seen, while I/R stimulated the ROS generation 
and mitochondrial depolarization in control livers, these effects were markedly 
enhanced in the ischemic livers of HC-fed mice but not in mice fed the CD diet (Fig. 4), 
consistent with the preceding findings on the mitochondrial GSH status, which is known 
to regulate MPT. Thus, HC feeding potentiates ROS stimulation and mitochondrial 
depolarization in vivo during hepatic I/R.  
Atorvastatin and squalene synthase inhibition prevent mitochondrial cholesterol  
loading and protect ob/ob mice from I/R injury. 
Given the above findings pointing to cholesterol as a potential culprit in the 
sensitization to hepatic I/R injury, we next examined the effect of cholesterol 
downregulation in ob/ob mice. We targeted two steps in the mevalonate pathway of the 
de novo cholesterol synthesis, namely, HMGCoA R, and the squalene synthase (Fig 
5A), examining the impact on the mitochondrial cholesterol trafficking. Although there 
was a trend for lower cholesterol levels in hepatic extracts of ob/ob mice after 
atorvastatin (Fig 5B), it significantly attenuated the increase in mitochondrial 
cholesterol (Fig. 5C). Biochemical analyses indicated that the atorvastatin was effective 
in decreasing the cholesterol levels in plasma (Fig 5D), suggesting that enhanced LDL 
uptake may contribute to the maintenance of total hepatic cholesterol pool following 
statin therapy and that mitochondrial cholesterol derives predominantly from de novo 
synthesis. Moreover, consistent with the increased mitochondrial cholesterol, ob/ob 
mice exhibited enhanced expression of StAR (Fig 5E), a mitochondrial cholesterol 
transporting polypeptide [26, 27]. Interestingly, atorvastatin therapy blunted StAR 
expression in ob/ob mice (Fig 5E). 
Since the inhibition of HMGCoAR can result in nonspecific effects independent of 
cholesterol regulation, We next tested the effect of squalene synthase inhibition by YM-
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53601, which is expected to prevent cholesterol synthesis from squalene without 
interference in the formation of non-sterol branch of the mevalonate pathway (Fig 5A). 
Neither atorvastatin nor the squalene synthase inhibitor affected the total cholesterol 
(14.3-16.6g cholesterol/mg protein) or the mitochondrial cholesterol pool (6.5-7.8g 
cholesterol/mg protein) in lean mice. However, the effect of YM-53601 on total 
cholesterol levels was similar to that observed by atorvastatin, but was able to 
significantly ameliorate the increase of the hepatic mitochondrial cholesterol in ob/ob 
mice (Fig 5B, C). In paralell with these observations, both atorvastatin and YM-53601 
protected ob/ob mice against I/R injury based on serum ALT values and histology 
examination following I/R injury (Fig. 6). Moreover, the H&E staining suggested that 
both therapeutic options ameliorated the hepatic steatosis of ob/ob mice that reflected 
decreased TG deposition (Supplemental Figure 2). Thus, these findings suggest that 
the newly synthesized cholesterol traffics to mitochondria and that its downregulation 
by statins of squalene synthase inhibition protects ob/ob mice from I/R liver injury. 
Restoration of mitochondrial GSH in ob/ob mice by atorvastatin and squalene 
synthase inhibition following I/R. 
Mitochondrial GSH is a critical antioxidant that regulates hepatocyte survival in 
response to oxidative stress, and hepatic I/R injury [28]. Since mitochondrial GSH 
regulation is dependent on cholesterol-mediated control of mitochondrial membrane 
dynamics, we next examined the effect of atorvastatin and YM-53601 on mitochondrial 
GSH homeostasis in ob/ob mice following I/R. Consistent with the effects observed on 
mitochondrial cholesterol pool, atorvastatin and YM-53601 restored the hepatic 
mitochondrial GSH content of sham control ob/ob mice to levels close to those 
observed in lean mice (Fig 7). Importantly, while this particular pool of GSH decreased 
further in ob/ob mice during I/R, both therapies significantly increased the 
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mitochondrial GSH levels in ob/ob mice following I/R (Fig 7), in agreement with the 
effect of atorvastatin and YM-53601 on the mitochondrial cholesterol content (Fig 5C). 
Similar protective findings were observed when the pool of mGSH is restored by GSH 
ethyl ester (not shown), a permeable form of GSH [21]. Consistent with the reversal of 
the mitochondrial GSH stores, atorvastatin and the squalene synthase inhibitor 
attenuated oxidative stress determined by the increase in MDA levels (Supplemental 
Fig 3). Thus, these findings indicate that the regulation of mitochondrial cholesterol 
content modulate the levels of mitochondrial GSH whose replenishment attenuates 
hepatic I/R injury. 
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DISCUSSION 
The mechanisms whereby hepatic steatosis sensitizes to I/R injury remain incompletely 
understood, and their elucidation may provide ways to increase the graft load available 
for use in diverse clinical settings requiring I/R. In this study, we analyzed the 
susceptibility of fatty livers with specific lipid profiles to I/R damage. Using nutritional 
and genetic models of hepatic steatosis, we observed that regardless of the qualitative 
appearance of steatosis (micro vs macrosteatosis), the presence of cholesterol, 
particularly in mitochondria, plays a previously unrecognized role in normothermic 
ischemic injury. Previous studies indicated that livers with microsteatosis induced by 
CD diet feeding were less sensitive to I/R damage than those with macrosteatosis seen 
in ob/ob mice [3]. Although we confirm this outcome here, we believe the relative 
qualitative aspect of steatosis plays a minor role in hepatic I/R susceptibility. While the 
steatosis of CD-fed mice may be microvesicular with respect to that of ob/ob mice, it is 
more macrovesicular than that of HC-fed mice. Moreover, although HC-fed mice 
exhibit microvesicular steatosis, these livers are as sensitive to I/R-induced damage as 
livers of ob/ob mice with macrovesicular steatosis. Rather than the relative contribution 
of micro vs macrosteatosis in discriminating the susceptibility to I/R injury, we provide 
evidence that hepatic cholesterol plays a so far unappreciated role in the sensitization of 
fatty liver to ischemic injury. CD-fed mice is characterized by steatosis with TG and 
FFA accumulation but unchanged cholesterol, in contrast to livers from HC-fed mice 
which exhibit a predominant cholesterol loading. Our findings showing a critical role of 
cholesterol in this process is consistent with previous reports in LDLr-/- mice or rabbits 
fed a high-cholesterol diet [29, 30]. Moreover, the susceptibility of LDLr-/- mice to 
hepatic I/R injury was ameliorated by anti TNF antibodies [29], pointing to a critical 
role of TNF in hepatic I/R damage. Considering previous findings favoring the 
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transition of steatosis to steatohepatitis by cholesterol [10], the present findings broaden 
the implications of cholesterol in liver pathology. 
The role of cholesterol in sensitizing to normothermic hepatic I/R injury is likely 
mediated by its trafficking and accumulation in mitochondria and subsequent depletion 
of mitochondrial GSH. Indeed, we observed in vivo mitochondrial depolarization and 
ROS generation by confocal imaging in HC-fed mice as opposed to CD-fed mice, 
consistent with the critical role of mitochondrial GSH in cell survival and defense 
against oxidative stress. Mitochondrial cholesterol loading is known to perturb 
membrane dynamics affecting selective carriers, including the GSH mitochondrial 
transporter but not the S-adenosyl-L-methionine (SAM) carrier [31]. Hence, unlike CD-
fed mice substantial hepatic mitochondrial GSH depletion is observed in HC-fed and 
ob/ob mice, both exhibiting marked susceptibility to I/R. Although I/R itself depletes 
hepatic GSH levels and mitochondrial GSH in paralell, the decrease of this latter 
specific pool is more dramatic upon mitochondrial cholesterol loading as seen in HC-
fed and ob/ob mice. Quite interestingly, we observed for the first time that livers from 
ob/ob mice exhibit enhanced expression of StAR, a mitochondrial cholesterol 
transporting polypeptide [26, 27], consistent with the mitochondrial cholesterol 
accumulation observed in these samples. Although we did not address the contribution 
of StAR in the regulation of mitochondrial cholesterol in ob/ob mice, it is conceivable 
that it may play a significant role as observed in human hepatocytes. Overexpression of 
StAR in HepG2 cells has been reported to cause the upregulation of 27-
hydroxycholesterol, a read-out metabolite of increased mitochondrial cholesterol pool 
[32]. Moreover, StAR silencing by siRNA has been shown to decrease this pool of 
cholesterol sensitizing human hepatocarcinoma cells to chemotherapy [33].  
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Additional evidence to support a role for cholesterol, particularly in mitochondria, in the 
susceptibility of ob/ob mice to hepatic I/R damage is provided by preventing cholesterol 
synthesis in the mevalonate pathway. Atorvastatin which targets HMGCoA R, the 
regulatory enzyme in the de novo cholesterol synthesis from acetyl-CoA,  
downregulates mitochondrial cholesterol loading, and consequently prevents 
mitochondrial GSH depletion during I/R. Quite intriguingly, atorvastatin also prevented 
the upregulation of StAR by an unknown mechanism, consistent with the above 
described effects on mitochondrial cholesterol. By targeting HMGCoA R, statins may 
have broad effects far from just preventing cholesterol synthesis, as the conversion of 
mevalonate into farnesyl-PP can branch into non-sterol intermediates including 
isoprenoids, which can regulate a number of target proteins posttranslationally. To 
confirm if the therapeutic effect of atorvastatin in ob/ob mice against hepatic I/R injury 
is due to the downregulation of cholesterol and its trafficking to mitochondria, we 
inhibited squalene synthase, which catalyzes the first committed step in cholesterol 
synthesis. Squalene synthase inhibition paralleled the effects observed with atorvastatin 
with respect to mitochondrial cholesterol depletion and subsequent mitochondrial GSH 
restoration, strongly suggesting that the beneficial effects of atorvastatin in hepatic I/R 
susceptibility is due to cholesterol regulation. Consistent with these effects, previous 
studies have shown that simvastatin reduces the mortality and hepatic injury after 
hemorrhage/resuscitation in rats or during liver I/R injury [34, 35]. In comparing the 
effect of atorvastatin in StAR and mitochondrial cholesterol regulation in ob/ob mice, it 
appears that the statin prevented StAR upregulation while it attenuated mitochondrial 
cholesterol loading, which suggests the possibility for the involvement of other StAR 
family members. Whether or not MLN64, which has been shown to mediate the egress 
of cholesterol from endosomes to mitochondria in the absence of Niemann-Pick type C1 
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protein [36], is involved in the upregulation of mitochondrial cholesterol in ob/ob mice 
remains to be established. Finally, it may give the impression that the pharmacological 
agents we use to modulate cholesterol levels exhibited unspecific effects reflected in the 
downregulation of TG levels in ob/ob mice. However, while these agents target 
HMGCoA reductase and squalene synthase specifically to prevent cholesterol synthesis, 
they may cause secondary effects in the regulation of other lipids including TG. Ob/ob 
mice is known to exhibit endoplasmic reticulum (ER) stress [36] and cholesterol 
upregulation has been shown to contribute to this response [37], which in turn leads to 
activation of ER-based transcription factors such as SREBPs [8, 9]. Thus, it is 
conceivable that cholesterol downregulation in ob/ob mice (by atorvastatin or YM-
53601) may secondarily contribute to SREBP1c downregulation via decreased ER 
stress, accounting for the reduction in TG content. 
In summary, by comparing side-by-side the susceptibility of fatty livers with disparate 
lipid composition, we uncovered a critical role of mitochondrial cholesterol in the 
sensitization of fatty livers againt ischemic injury and that this effect is due to 
mitochondrial GSH depletion. Consistent with this outcome, previous studies reported 
the depletion of this pool of GSH during hepatic I/R damage, and its restoration by GSH 
ethyl ester [37] or SAM [38] protected steatotic livers against I/R damage. Although 
this concept remains to be tested in human fatty liver, mitochondrial GSH depletion has 
been shown in nonalcoholic steatohepatitis [39] which is associated with increased free 
cholesterol accumulation and StAR overexpression [40]. If confirmed the role of 
cholesterol and its accumulation in mitochondria in human fatty livers and its 
correlation with graft failure, then analyzing the presence of cholesterol or cholesterol-
related proteins such as StAR in steatotic donor grafts may represent a valuable 
discriminating tool to expand the pool of available organs for transplantation. 
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FIGURE LEGENDS. 
Figure 1. Nutritional and genetic models of micro and macrosteatosis. Livers from mice 
were fed a HC or CD diet or from ob/ob mice were analyzed for TG (A), cholesterol (B) 
or FFA (C) levels biochemically. In addition, samples were taken for oil red (D) or 
filipin (E) staining to monitor the appearance of neutral lipids or free cholesterol, 
respectively. Results are the mean SD of 4-6 mice per group. Images from D and E are 
representative of 4-6 mice per group. *p<0.05 vs control group. Magnification of 
images in D is x20, while in E is x10. 
Figure 2. Differential susceptibility of steatotic livers to I/R injury. Mice fed CD or HC 
diets were analyzed for serum transaminase levels (A), or histology (B) to assess their 
sensitivity to I/R. Alternatively, ob/ob mice were used to determine transaminase values 
(C) or histology after I/R. Results are the mean SD of 4-6 mice per group. *p<0.05 vs 
corresponding control groups with or without I/R. Magnification of images in B is x20. 
Figure 3. Cholesterol and GSH compartmentation after I/R. Livers from mice fed CD 
or HC diets were processed for mitochondrial isolation to analyze cholesterol content 
(A). Alternatively, samples were used for GSH determination in homogenate (B) or 
mitochondria (C). Results are the mean SD of 5-7 mice. *p<0.05 vs control mice. 
#p<0.05 vs control or CD-fed mice. 
Figure 4. In vivo confocal imaging of mitochondrial polarization and ROS generation 
after I/R. In vivo two-photon confocal microscopy during partial I/R in mice fed CD or 
HC diets. ROS generation and mitochondrial polarization were assessed from DCF and 
TMRE fluorescence. The imaging of the liver of living mice was performed using 
spectral confocal inverted microscope Leica TCS SP5. The emissions were acquired with 
internal spectral detector (PMT) at high speed in order to avoid the movement from 
animal breathing and heart beating during acquisition.  
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Figure 5. Effect of atorvastatin and squalene synthase inhibition on mitochondrial 
cholesterol trafficking. A, mevalonate pathway showing the branching of farnesyl-PP 
into cholesterol synthesis via squalene formation or the formation of non-sterol 
intermediates and the target of statins and YM-53601. Livers from lean and ob/ob mice 
were processed for cholesterol analyses in homogenates (B), mitochondria (C) as well 
as in plasma (D). E, shows the mRNA expression for StAR in livers  from lean and 
ob/ob mice with or without atorvastatin treatment. Results are the mean SD of 4-6 mice 
per group. *p<0.05 vs. control lean mice; # p<0.05 vs. ob/ob mice. 
Figure 6. Atorvatatin and YM-53601 protect ob/ob mice from I/R injury. Ob/ob mice 
were pretreated with atorvastatin or YM-53601 for seven days before I/R at the dose of 
10mg/kg or 15mg/kg, respectively, or vehicle. 6 hours after reperfusion serum or liver 
biopsies were processed for assessment of transaminases (A) or histology (B). Results 
are the mean SD of 4-6 mice. *p<0.05 vs ob/ob sham mice;# p<0.05 vs. vehicle-treated 
ob/ob mice. Magnification of images in B is x20. 
Figure 7. Mitochondrial GSH levels in ob/ob mice following I/R with or without 
atorvastatin or YM-53601 therapy. Samples from ob/ob mice following I/R with or 
without atorvastatin and YM-53601 therapy were processed for mitochondrial isolation 
and GSH determination. Results are the mean SD of 5-7 mice per group. *p<0.05 vs 
lean or ob/ob sham mice, **p<0.05 vs. ob/ob sham mice; #p<0.05 vs. ob/ob mice 
following I/R.  
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SUPPLEMENTAL FIGURES 
Figure 1. Hepatic lipid profile in ob/ob mice. Livers from ob/ob mice were processed 
for biochemical determination of triglycerides, cholesterol and free fatty acids. Results 
are the mean SD of 5-7 mice per group. *p<0.05 vs. lean mice. 
Figure 2. Hepatic triglycerides in ob/ob mice following atorvastatin or YM53601 
therapy. Liver samples from ob/ob mice with or without atorvastatin or YM-53601 were 
processed for biochemical determination of triglycerides. Results are the mean SD of 4-
6 mice per group. *p<0.05 vs. ob/ob mice with treatment. 
Figure 3. Malondialdehyde levels in ob/ob mice following hepatic I/R. ob/ob mice were 
treated or not with atorvastatin or YM-53601 before undergoing hepatic I/R. Liver 
samples were collected after reperfusion (6 hrs) and processed for MDA determination 
by the thibarbituric acid assay. Results are the mean SD of 4-6 mice per group. p<0.05 
vs. sham ob/ob mice; #p<0.05 vs ob/ob mice. 
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